Future Stem Cell Clinical Trials

UCLA

Preparations are ongoing towards a Phase 1 clinical trial using genetically modified autologous hematopoietic stem cells (HSC) for the immunotherapy of advanced stage melanoma.


UC Irvine

Chronic Ischemic Stroke

Study of Modified Stem Cells (SB623) in Patients With Chronic Motor Deficit From Ischemic Stroke (ACTISSIMA)

Controlled study of stereotactic, intracranial injection of SB623 cells in patients with fixed motor deficits from ischemic stroke

Ages Eligible for Study: 18 Years to 75 Years
Genders Eligible for Study: Both

Contacts
Steven C. Cramer, MD, 949-824-3990 or stemcell@uci.edu


Traumatic Brain Injury

A Study of Modified Stem Cells in Traumatic Brain Injury (TBI) (STEMTRA)

The primary purpose of the clinical study is to evaluate the clinical efficacy of intracranial administration of SB623 cells on patients with chronic motor deficit from Traumatic Brain Injury. A secondary purpose of the study is 1) to evaluate the effect of intracranial administration of SB623 cells on disability parameters and 2) to evaluate the safety and tolerability of intracranial administration of SB623 cells. Patients with stable, chronic motor deficits secondary to focal traumatic brain injury must be between 12-36 months post TBI

Ages Eligible for Study: 18 Years to 75 Years
Genders Eligible for Study: Both

Contacts
Steven C. Cramer, MD, 949-824-3990 or stemcell@uci.edu